3P Biopharmaceuticals, a contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing for biological products, has installed a new 500-liter stainless steel fermenter to complement its existing capacity for protein production from bacteria and yeast with fermentation technology.
3P Biopharmaceuticals, a contract development and manufacturing organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has signed a manufacturing agreement with SpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases.
3P Biopharmaceuticals, a contract development and manufacturing organization (CDMO) specialized in the process development and GMP manufacturing of biologics, and the Swedish biotechnology company Intervacc AB, have secured the large-scale production of the vaccine against equine strangles called Strangvac. The technology transfer and scale-up of the manufacturing process with verification of reproducibility for Strangvac production has been completed. Intervacc intends to submit a registration application for Strangvac at the end of 2019. In order to accomplish this goal, large-scale commercial batches will be manufactured in compliance with GMP.
3P Biopharmaceuticals, a contract development and manufacturing organization (CDMO) specialized in the process development and GMP manufacturing of biologics, has signed a collaboration agreement with the Dutch biotech company Xenikos that will cover the global manufacturing of Xenikos’ proprietary lead product candidate T-Guard.
Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced a partnership with 3P Biopharmaceuticals, a leader in the production of biological drugs, for the manufacture of interferon alpha (IFN?). Today’s collaboration follows the recent acquisition of the technology for the manufacture of IFN? by Neovacs from AMEGABIOTECH.